including semaglutide branded as Wegovy or Ozempic, and tirzepatide (dual GIP/GLP-1 receptor agonist) branded as Zepbound or Mounjaro, for the management of obesity, type 2 diabetes, and other metabolic conditions increases, so too does the need to assess the advantages and potential downsides of long-term use
8 Concerningly, lifestyle improvements are often difficult to sustain, underscoring the potential benefits of early initiation and background therapy with GLP-1RA due to its benefits on metabolic disorders (Table 3) and chronic liver disease
Many trials report overall efficacy but lack adequate power or pre-specified plans to detect sex differences (Raparelli et al., 2020)
Want to help spread the word
FDA listed warning letters issued to internet retailers/providers of various compounded drug under the term Telehealth on its webpage: Compounding: Inspections, Recalls, and other Actions